Introduction
The dapagliflozin patent disputes that made headlines in the UK in April 2025 — where the High Court reaffirmed a strict plausibility standard requiring reasonable scientific grounds for therapeutic effect claims at the filing date — are not just a UK story. Japan has been moving in a parallel direction.
Japanese courts and the JPO have increasingly applied a stricter post-filing plausibility approach to pharmaceutical patents, requiring that the therapeutic utility claimed in a patent was supported by scientific evidence at the priority date — not just asserted. For life sciences companies mapping Japan’s competitive patent landscape, this shift changes how existing pharma patents should be read and what blocking risk they actually represent.
Some patents that appear to foreclose a therapeutic area in the Japanese landscape are now more challengeable than their grant status alone suggests. And the patent cliff approaching through 2030 is opening specific whitespace windows in previously protected spaces — but only where secondary patent thickets have genuinely weakened, not just where primary compound patents have expired. This article maps both dimensions.
Japan’s Plausibility Standard: Where It Stands in 2025–2026
What Japanese courts and the JPO now require: Japan’s patent law requires that a patent specification enable a person skilled in the art to practice the invention and that the claimed utility be supported at the filing date. Following decisions by Japanese courts applying increased rigour to pharmaceutical compound and biological therapeutic claims, the standard has effectively tightened: patents asserting broad therapeutic use claims need to demonstrate a credible scientific basis for the claimed effect in the specification itself, with experimental data at filing that makes the therapeutic utility plausible to a skilled person reading the specification at priority date. Post-filing data can corroborate, but cannot rescue, a claim that lacked adequate support at filing.
Alignment with — and differences from — the UK approach: The direction of travel in Japan is parallel to the UK High Court’s April 2025 dapagliflozin ruling, which reaffirmed a strict plausibility standard and explicitly declined to follow the EPO’s more permissive post-G2/21 approach. However, Japan’s plausibility standard operates through the JPO examination framework and Japanese court interpretation of the utility and enablement requirements — not through the same legal doctrine as UK insufficiency. The practical effect is similar: broad therapeutic claims with thin filing-date experimental support are more vulnerable than they were under the more permissive standards of five years ago. But the route to challenge differs by jurisdiction.
This parallel between Japan and UK standards is covered in depth in our analysis of Japan’s pharmaceutical patent linkage system and its implications for invalidity strategy — which sets out how Japan’s distinct regulatory and patent framework creates different strategic requirements from the US or European approaches that most international pharma teams are more familiar with.
The practical implication for the landscape: Patents filed with broad therapeutic use claims and limited filing-date experimental support — particularly in antibody, biologic, and combination therapy spaces where wide functional claiming is common — carry higher validity risk under the current JPO and court approach than they did under prior standards. A landscape analysis that doesn’t account for this validity shift is over-reading the blocking risk those patents represent.
JPO CONTEXT: The JPO’s examination guidelines on working examples and therapeutic utility demonstration have been applied with increasing strictness through 2024–2025. JPO examiners and appeal board decisions in pharmaceutical cases are citing the need for specification-level plausibility with greater frequency. Japanese courts hearing validity challenges are following a similar trend. The standard is not yet codified with the clarity of UK case law, but the direction of travel is consistent.
What This Means for Reading Japan’s Competitive Pharma Landscape
Landscape analysis serves two purposes: it shows you which patents block your path, and it shows you where genuine whitespace exists. Both of these outputs are affected by the plausibility shift.
Why treating all granted patents as equivalent blocking risks over-reads the landscape: A patent granted under the more permissive standards of 2018 or 2019, covering a broad therapeutic class with limited working examples, carries a materially different invalidity risk profile in 2026 than at the time of grant. The JPO that granted it and the courts that would adjudicate a challenge are now applying stricter plausibility scrutiny. A landscape that treats that patent as a high-risk blocker — equivalent in strength to a patent with comprehensive filing-date experimental support — is assigning it more blocking power than it actually has in the current environment.
Validity risk weighting: An accurate Japan life sciences landscape applies a validity risk filter to the blocking patents it identifies. For each high-priority blocker, the analysis asks: does the specification demonstrate therapeutic plausibility with adequate filing-date experimental support? If not, the patent should be flagged as a potential challenge candidate — carrying higher invalidity risk than its grant status suggests — rather than treated as a structurally solid block on the technology space.
Where whitespace is opening: As blocking patents become more challengeable under the stricter plausibility standard, and as primary compound patents in major therapeutic areas expire through the patent cliff, genuine whitespace is opening in spaces that appeared foreclosed. The whitespace is real — but identifying it accurately requires understanding which blocking patents are genuinely strong and which are vulnerable, not just mapping patent density as a proxy for blockage.
“The Japan life sciences landscape in 2026 doesn’t look the same as it did in 2020. The plausibility shift means some of the patents that appear to foreclose therapeutic areas are more challengeable than their grant status suggests. A landscape that reads those patents at face value is over-estimating the blockage. A landscape that applies validity risk weighting gives a more accurate picture of where R&D investment can move.”
The Patent Cliff Dimension: Japan and Global Expiries
Scale and therapeutic areas: Japan’s pharmaceutical market — the third-largest in the world by value — is experiencing the same patent cliff dynamics as the US and UK. Major drugs approaching expiry through 2030 span diabetes (SGLT2 inhibitors, GLP-1 agonists), oncology (checkpoint inhibitors, targeted therapies), immunology, and cardiovascular. For each expiring product in Japan, the competitive landscape question is the same: how much secondary patent coverage remains, how valid is it under Japan’s current plausibility standard, and where is the genuine competitive space for generic or biosimilar entry or for competing innovator development?
Secondary patent coverage in Japan: In Japan, as in other major markets, the approaching cliff is defined less by primary compound patent expiry than by the secondary patent landscape. Formulation patents, dosing regimen patents, manufacturing process patents, and polymorphic form patents extend effective exclusivity in many therapeutic areas well beyond the primary compound expiry. For generic manufacturers, the secondary landscape in Japan requires the same scrutiny as the primary compound — and the plausibility shift creates a specific opportunity to challenge secondary patents filed with limited specification support in Japan during the broad-claiming era.
Generic and biosimilar entry considerations: Japan’s pharmaceutical regulatory system — including its patent linkage mechanism, PMDA coordination, and the role of the JPO’s reexamination proceedings in validity challenges — creates a distinct generic entry pathway. Understanding which blocking patents in the Japan landscape are genuinely solid versus potentially vulnerable under the current plausibility standard is the foundation of both the FTO and the invalidity strategy for generic and biosimilar manufacturers planning Japanese market entry.
R&D Portfolio Strategy Implications
For life sciences companies with R&D programmes targeting the Japanese market, the post-plausibility landscape has three specific strategic implications. As our analysis of how patent landscape analysis can support R&D strategy decisions sets out, a landscape that reflects current validity standards — not just filing density — gives R&D teams a more accurate picture of where investment is genuinely constrained and where it can move.
- File with stronger specification support for Japan prosecution. Patents filed for Japanese prosecution in the current environment should include more comprehensive experimental data at filing than was standard practice five years ago. The stricter plausibility application by JPO examiners and Japanese courts means that applications relying on post-filing data to support broad therapeutic claims face a higher risk of rejection or invalidity challenge. Front-loading the specification with working examples that demonstrate plausibility across the claimed scope is the prosecution strategy that reflects the current standard.
- Challenge old blocking patents more actively. Landscape analysis may reveal competitor patents in your target therapeutic area that are blocking on their face but vulnerable under Japan’s current plausibility standard. Patents filed with broad functional claims and limited working examples during the more permissive era are candidates for invalidity challenge before the JPO’s reexamination proceedings — a route that is less expensive and faster than full court proceedings and creates genuine freedom to operate where challenge succeeds.
- Map whitespace more accurately. A landscape that applies validity risk weighting to the blocking patents it identifies will show more available whitespace than a raw patent density map. Therapeutic areas that appear densely covered may have genuine openings once vulnerable blocking patents are filtered out. Identifying those openings — and filing to secure positions in them before competitor continuation strategies refill the space — is the R&D portfolio strategy that the post-plausibility landscape supports.
How Our Landscape Analysis Service Covers Japan’s Life Sciences Market
Our patent landscape analysis service covers Japan’s pharmaceutical and biotech patent space with JPO-specific validity risk weighting — applying the post-2025 plausibility standard to assess which blocking patents in the competitive landscape carry genuine validity resilience versus which are vulnerable to challenge under current Japanese standards. For companies planning Japanese market entry or R&D investment in therapeutic areas with existing Japanese patent coverage, we provide a competitive filing trend analysis and a validity risk assessment that reflects Japan’s current plausibility approach. For generic and biosimilar manufacturers, we structure landscape analysis around the secondary patent thicket — identifying which blocking patents are most vulnerable to JPO reexamination challenge and which represent genuinely solid blocks on market entry.
Mapping Japan’s life sciences competitive landscape? Our service applies Japan’s post-2025 plausibility standard to give you an accurate picture of genuine blocking risk — and where whitespace is genuinely available. → Contact Us
Conclusion: The Takeaway
Japan’s life sciences patent landscape in 2026 doesn’t read the same way it did in 2020. A tighter plausibility standard means that some of the blocking patents which appeared to foreclose therapeutic areas carry higher invalidity risk than their grant status alone suggests. The patent cliff approaching through 2030 is creating specific competitive windows — but the windows are defined by secondary patent vulnerability, not just primary compound expiry.
For R&D teams mapping Japanese competitive IP, the output that matters is not just which patents exist — it is which patents genuinely block movement and which are challengeable. That distinction is what a validity risk-weighted Japan landscape provides. And in the current plausibility environment, that distinction is wider than it has been for a decade.
